- Home
- CAST vs ANTX Comparison
CAST vs ANTX Comparison
Compare CAST & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAST | ANTX |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.2M | 172.9M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CAST | ANTX |
|---|---|---|
| Price | $1.42 | $4.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $2.00 |
| AVG Volume (30 Days) | ★ 1.3M | 186.3K |
| Earning Date | 06-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.00 |
| 52 Week High | $12.20 | $7.19 |
Technical Indicators
Market Signals| Indicator | CAST | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 36.32 |
| Support Level | $1.24 | $3.91 |
| Resistance Level | $1.55 | $5.15 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 64.52 | 12.50 |
Price Performance
Historical ComparisonAbout CAST FreeCast Inc. Class A Common Stock
FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and streaming services.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.